13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001920938
Total reported value
$2.7B
$2.7B
88 檔
19.3%
In Q1 2026, Braidwell LP's U.S. equity holdings reached a combined market value of $2.7B, distributed across 88 disclosed stock positions.
Braidwell LP executed strategic sector rebalancing during Q1 2026, establishing 31 new positions while fully exiting 16 holdings and trimming 32 positions.
In terms of portfolio concentration, the top 5 core holdings (including CAI, GH 1.25 02-15-31, RGEN 1 12-15-28) accounted for 19.3% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CAI | Caris Life Sciences Inc | Stock-Other | 4.78% | +0.66% | +2.47% | |
| 2 | GH 1.25 02-15-31Bond | Guardant Health Inc | Bond | 3.42% | -3.42% | EXIT | |
| 3 | RGEN 1 12-15-28Bond | Repligen CORP | Bond | 3.29% | -2.68% | — | |
| 4 | NEO 0.25 01-15-28Bond | Neogenomics Inc | Bond | 3.06% | -2.44% | — | |
| 5 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.87% | -0.77% | -13.23% | |
| 6 | GKOS | Glaukos CORP | Stock-Healthcare | 2.74% | +0.32% | -17.19% | |
| 7 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 2.63% | -2.63% | EXIT | |
| 8 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.60% | -0.07% | -26.66% | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.52% | -0.38% | -29.40% | |
| 10 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 2.47% | +0.53% | -54.95% | |
| 11 | IRTC | Irhythm Holdings Inc | Stock-Healthcare | 2.40% | +0.48% | +180.75% | |
| 12 | NUVL | Nuvalent Inc-a | Stock-Other | 2.39% | -2.39% | EXIT | |
| 13 | KOD | Kodiak Sciences Inc | Stock-Other | 2.31% | +0.27% | -12.26% | |
| 14 | CGON | Cg Oncology Inc | Stock-Other | 2.22% | -2.22% | EXIT | |
| 15 | ATEC 0.75 03-15-30Bond | Alphatec Holdings Inc | Bond | 2.11% | +0.34% | — | |
| 16 | ARGX | Argenx Se - Adr | Stock-Healthcare | 2.07% | -1.46% | +173.93% | |
| 17 | HNGE | Hinge Health Inc-a | Stock-Other | 1.87% | +2.21% | +11.54% | |
| 18 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.84% | -0.30% | +21.61% | |
| 19 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 1.76% | +0.43% | +238.13% | |
| 20 | KRYS | Krystal Biotech Inc | Stock-Healthcare | 1.57% | +0.20% | -9.74% | |
| 21 | SYRE | Spyre Therapeutics Inc | Stock-Other | 1.57% | +1.32% | -42.93% | |
| 22 | GH | Guardant Health Inc | Stock-Healthcare | 1.54% | -0.72% | — | |
| 23 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 1.52% | +0.14% | +15.10% | |
| 24 | GENB | Generate Biomedicines Inc | Stock-Other | 1.50% | +0.55% | — | |
| 25 | MBX | Mbx Biosciences Inc | Stock-Other | 1.49% | -0.04% | +46.52% | |
| 26 | BTSG | Brightspring Health Services | Stock-Other | 1.44% | +0.10% | -14.99% | |
| 27 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.43% | -0.83% | -27.02% | |
| 28 | NEO | Neogenomics Inc | Stock-Healthcare | 1.39% | +1.26% | +21.25% | |
| 29 | APGE | Apogee Therapeutics Inc | Stock-Other | 1.34% | -1.34% | EXIT | |
| 30 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.31% | -0.05% | +66.39% | |
| 31 | CDNA | Caredx Inc | Stock-Other | 1.26% | +0.03% | +37.09% | |
| 32 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 1.19% | -0.16% | -7.34% | |
| 33 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 1.17% | -0.05% | +25.27% | |
| 34 | PEN | Penumbra Inc | Stock-Healthcare | 1.15% | -1.15% | EXIT | |
| 35 | TMDX | Transmedics Group Inc | Stock-Healthcare | 1.09% | +0.41% | +4.46% | |
| 36 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 1.07% | -1.07% | EXIT | |
| 37 | DYN | Dyne Therapeutics Inc | Stock-Other | 1.02% | -0.26% | +13.78% | |
| 38 | MRVI | Maravai Lifesciences Hldgs-a | Stock-Other | 0.97% | +1.04% | +22.59% | |
| 39 | ILMN | Illumina Inc | Stock-Healthcare | 0.94% | -0.94% | EXIT | |
| 40 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.94% | +0.66% | -25.69% | |
| 41 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.94% | -0.94% | EXIT | |
| 42 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.91% | +0.24% | -19.83% | |
| 43 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.90% | +0.67% | — | |
| 44 | DHR | Danaher CORP | Stock-Healthcare | 0.88% | +0.18% | +17.85% | |
| 45 | ✓ | Establishment Labs Holdings In | Stock-Other | 0.88% | -0.88% | EXIT | |
| 46 | TECX | Tectonic Therapeutic Inc | Stock-Other | 0.87% | -0.11% | -8.67% | |
| 47 | NTRA | Natera Inc | Stock-Healthcare | 0.86% | -0.06% | +15.70% | |
| 48 | CRVS | Corvus Pharmaceuticals Inc | Stock-Other | 0.86% | +0.32% | — | |
| 49 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.80% | -0.80% | EXIT | |
| 50 | ✓ | Zura Bio LTD | Stock-Other | 0.79% | +0.08% | +25.42% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | GLUE | Monte Rosa Therapeutics Inc | +1.3% | +238.13% | Add |
| 2 | ARGX | Argenx Se - Adr | +1.2% | +173.93% | Add |
| 3 | IRTC | Irhythm Holdings Inc | +1.2% | +180.75% | Add |
| 4 | 260 | Centessa Pharmaceuticals-adr | +0.9% | -9.21% | Trim |
| 5 | DNTH | Dianthus Therapeutics Inc | +0.8% | -29.40% | Trim |
| 6 | DRUG | Bright Minds Biosciences Inc | +0.5% | +66.39% | Add |
| 7 | MBX | Mbx Biosciences Inc | +0.5% | +46.52% | Add |
| 8 | KOD | Kodiak Sciences Inc | +0.5% | -12.26% | Trim |
| 9 | CDNA | Caredx Inc | +0.3% | +37.09% | Add |
| 10 | ✓ | Zura Bio LTD | +0.3% | +25.42% | Add |
| 11 | TECX | Tectonic Therapeutic Inc | +0.3% | -8.67% | Trim |
| 12 | NEO 0.25 01-15-28Bond | Neogenomics Inc | +0.2% | — | Unchanged |
| 13 | MRVI | Maravai Lifesciences Hldgs-a | +0.1% | +22.59% | Add |
| 14 | DYN | Dyne Therapeutics Inc | +0.1% | +13.78% | Add |
| 15 | ACAD | Acadia Pharmaceuticals Inc | +0.1% | +21.61% | Add |
| 16 | PEN | Penumbra Inc | +0.1% | -4.36% | Trim |
| 17 | SRZN | Surrozen Inc | 0% | -15.72% | Trim |
| 18 | NTRA | Natera Inc | 0% | +15.70% | Add |
| 19 | KNSA | Kiniksa Pharmaceuticals International, plc | 0% | -13.16% | Trim |
| 20 | TMO | Thermo Fisher Scientific Inc | 0% | +15.10% | Add |
| 21 | XFOR | X4 Pharmaceuticals Inc | 0% | -2.85% | Trim |
| 22 | BTSG | Brightspring Health Services | 0% | -14.99% | Trim |
| 23 | DHR | Danaher CORP | 0% | +17.85% | Add |
| 24 | XENE | Xenon Pharmaceuticals Inc | 0% | -26.66% | Trim |
| 25 | KRYS | Krystal Biotech Inc | 0% | -9.74% | Trim |
| 26 | LUNG | Pulmonx CORP | 0% | — | Unchanged |
| 27 | KIDS | Orthopediatrics CORP | 0% | — | Unchanged |
| 28 | APGE | Apogee Therapeutics Inc | -0.1% | -16.76% | Trim |
| 29 | HNGE | Hinge Health Inc-a | -0.1% | +11.54% | Add |
| 30 | CMPX | Compass Therapeutics Inc | -0.1% | -29.48% | Trim |
| 31 | SYRE | Spyre Therapeutics Inc | -0.1% | -42.93% | Trim |
| 32 | TMDX | Transmedics Group Inc | -0.1% | +4.46% | Add |
| 33 | GRAL | Grail Inc | -0.1% | — | Unchanged |
| 34 | CLDX | Celldex Therapeutics Inc | -0.2% | -27.02% | Trim |
| 35 | KYMR | Kymera Therapeutics Inc | -0.2% | -25.69% | Trim |
| 36 | ILMN | Illumina Inc | -0.2% | -15.00% | Trim |
| 37 | BMRN | Biomarin Pharmaceutical Inc | -0.2% | -17.37% | Trim |
| 38 | EOLS | Evolus Inc | -0.2% | — | Unchanged |
| 39 | RGEN | Repligen CORP | -0.2% | -41.92% | Trim |
| 40 | RGEN 1 12-15-28Bond | Repligen CORP | -0.3% | — | Unchanged |
| 41 | NUVL | Nuvalent Inc-a | -0.3% | -14.73% | Trim |
| 42 | CGON | Cg Oncology Inc | -0.3% | -47.35% | Trim |
| 43 | HROW | Harrow Inc | -0.3% | -47.03% | Trim |
| 44 | FULC | Fulcrum Therapeutics Inc | -0.3% | +2.41% | Add |
| 45 | ISRG | Intuitive Surgical Inc | -0.3% | -7.34% | Trim |
| 46 | ✓ | Engene Holdings Inc | -0.3% | -21.54% | Trim |
| 47 | NEO | Neogenomics Inc | -0.4% | +21.25% | Add |
| 48 | NRIX | Nurix Therapeutics Inc | -0.4% | -19.83% | Trim |
| 49 | INSP | Inspire Medical Systems Inc | -0.4% | +25.27% | Add |
| 50 | NBIX | Neurocrine Biosciences Inc | -0.5% | -13.23% | Trim |
According to official SEC Form 13F filings, Braidwell LP reported a total U.S. public equity portfolio value of $2.7B across 88 disclosed positions in Q1 2026.
During Q1 2026, Braidwell LP's top holdings by market value included CAI (4.8%)、GH 1.25 02-15-31 (3.4%)、RGEN 1 12-15-28 (3.3%). The largest single position, CAI, represented 4.8% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ATEC 0.75 03-15-30
市值: $63.4M
Top Position Liquidated / Trimmed
IRTC 1.5 09-01-29
前期市值: $72.8M
In Q1 2026, Braidwell LP made 98 total portfolio adjustments, initiating 31 new buys, adding to 19 positions, trimming 32 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.